Search details
1.
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Am J Hematol
; 95(11): 1324-1333, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32744738
2.
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma.
Blood Adv
; 7(5): 744-755, 2023 03 14.
Article
in English
| MEDLINE | ID: mdl-35439292
3.
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Am J Hematol
; 92(6): E105-E107, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28295510
4.
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
Leuk Lymphoma
; 63(3): 599-607, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34720034
5.
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Clin Nucl Med
; 46(8): 627-634, 2021 Aug 01.
Article
in English
| MEDLINE | ID: mdl-34115706
6.
Des lymphocytes supérieurs à 5 000/mm3 plus de 3 mois.
Rev Prat
; 66(9): 1016-1019, 2016 Nov.
Article
in French
| MEDLINE | ID: mdl-30512374
Results
1 -
6
de 6
1
Next >
>>